NASDAQ:MACK

Merrimack Pharmaceuticals (MACK) Stock Forecast, Price & News

$12.52

0.00 (0.00%)

(As of 05/31/2023 ET)

Compare

Today's Range: $12.40
▼
$12.53
50-Day Range: $11.87
▼
$13.07
52-Week Range: $3.00
▼
$13.66

Volume: 20,111 shs
Average Volume: 108,520 shs
Market Capitalization: $178.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Merrimack Pharmaceuticals MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
5.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.57
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$1.85 M Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

863rd out of 1,006 stocks

Pharmaceutical Preparations Industry

431st out of 492 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Merrimack Pharmaceuticals.

3.0

Short Interest

Percentage of Shares Shorted
5.05% of the outstanding shares of Merrimack Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Merrimack Pharmaceuticals has a short interest ratio ("days to cover") of 9.5.
Change versus previous month
Short interest in Merrimack Pharmaceuticals has recently decreased by 8.79%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Merrimack Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Merrimack Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MACK.

3.1

News and Social Media Coverage

News Sentiment
Merrimack Pharmaceuticals has a news sentiment score of 1.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Merrimack Pharmaceuticals this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Merrimack Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merrimack Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,849,997.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
28.87% of the stock of Merrimack Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
59.74% of the stock of Merrimack Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Merrimack Pharmaceuticals is -104.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Merrimack Pharmaceuticals is -104.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Merrimack Pharmaceuticals has a P/B Ratio of 9.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Merrimack Pharmaceuticals (NASDAQ:MACK) Stock

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Stock News Headlines

June 1, 2023 | americanbankingnews.com

Financial Analysis: Merrimack Pharmaceuticals (NASDAQ:MACK) versus Rallybio (NASDAQ:RLYB)

May 14, 2023 | americanbankingnews.com

Merrimack Pharmaceuticals (NASDAQ:MACK) Upgraded at StockNews.com

June 1, 2023 | Vantage Point (Ad)

Instantly Find Hidden Trade Opportunities

There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.

May 7, 2023 | americanbankingnews.com

Merrimack Pharmaceuticals (NASDAQ:MACK) Raised to "Hold" at StockNews.com

May 3, 2023 | americanbankingnews.com

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Short Interest Up 6.7% in April

April 22, 2023 | americanbankingnews.com

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Short Interest Update

April 19, 2023 | finance.yahoo.com

Retail investors account for 38% of Merrimack Pharmaceuticals, Inc.'s (NASDAQ:MACK) ownership, while hedge funds account for 33%

April 16, 2023 | marketwatch.com

Global Receptor Tyrosine Protein Kinase ERBB 3 Market Size Emerging Trends and Will Generate New Growth Opportunities Status 2030 By VMReports

June 1, 2023 | Vantage Point (Ad)

Instantly Find Hidden Trade Opportunities

April 15, 2023 | usnews.com

Merrimack Valley High School

April 3, 2023 | thestreet.com

Why Merrimack Pharmaceuticals (MACK) Stock is Down in After-Hours Trading Today

March 30, 2023 | nytimes.com

Track Covid-19 in Merrimack County, New Hampshire

March 25, 2023 | americanbankingnews.com

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Director Buys $1,849,996.80 in Stock

March 22, 2023 | marketwatch.com

Oncology Injection Drug Market Size and Forecast till 2031

March 15, 2023 | msn.com

Why Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket

March 10, 2023 | nytimes.com

Merrimack Won a Title, but the N.C.A.A. Tournament Will Have to Wait

March 9, 2023 | msn.com

Histogen GAAP EPS of -$3.46, revenue of $3.77M misses by $0.35M

March 9, 2023 | finance.yahoo.com

Merrimack Reports Full Year 2022 Financial Results

March 7, 2023 | yahoo.com

Merrimack, United States - Weather Forecasts | Maps | News - Yahoo Weather

February 24, 2023 | uk.finance.yahoo.com

The Global Liposomal Products Market is forecast to grow by $3,183.63 mn during 2022-2027, accelerating at a CAGR of 9.65% during the forecast period

February 22, 2023 | finance.yahoo.com

Radionetics Oncology Appoints Istvan Molnar, M.D. as Chief Medical Officer

February 19, 2023 | marketwatch.com

Global HER2-Positive Breast Cancer Market to by In-depth Analysis of Revenue Forecast and Competitive Landscape 2030 By VMReports

December 13, 2022 | finance.yahoo.com

Bullish Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insiders filled their treasuries with US$574k worth of stock over last year

December 5, 2022 | finance.yahoo.com

Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan

November 16, 2022 | finance.yahoo.com

Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More

November 10, 2022 | finance.yahoo.com

Hedge funds investors control 44% of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) and were rewarded last week after stock increased 228%

November 9, 2022 | nasdaq.com

Merrimack Soars On Promising Data From Ipsen's NAPOLI-3 Trial

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Company Calendar

Last Earnings: 3/09/2023
Today: 5/31/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:MACK
CUSIP: 59032810
CIK: 1274792
Web: www.merrimackpharma.com
Phone: 617-720-8606
Fax: 617-491-1386
Employees: 426
Year Founded: 2000

Profitability

EPS (Most Recent Fiscal Year): ($0.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,540,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -10.32%
Return on Assets: -10.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 42.39
Quick Ratio: 42.39

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.34 per share
Price / Book: 9.34

Miscellaneous

Outstanding Shares: 14,260,000
Free Float: 10,143,000
Market Cap: $178.54 million
Optionable: Optionable
Beta: 1.84

Social Links

Key Executives

Mr. Gary L. Crocker M.B.A. (Age 70)
MBA, Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
Comp: $105.44k

Dr. Ulrik B. Nielsen Ph.D. (Age 50)
Co-Founder & Independent Director
Comp: $102.76k

Dr. Anthony J. Sinskey Ph.D. (Age 82)
Sc.D., Co-Founder and Scientific Advisor

Geoffrey Grande C.F.A.
Sr. Director of Communications

Ms. Ellen K. Forest (Age 58)
Head of HR

Dr. Fazal R. Khan Ph.D. (Age 72)
Sr. VP of Manufacturing

Dr. Daryl C. Drummond Ph.D. (Age 53)
Head of Research

Mr. Timothy R. Surgenor (Age 62)
Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MACK Stock - Frequently Asked Questions

How have MACK shares performed in 2023?: Merrimack Pharmaceuticals' stock was trading at $11.46 at the start of the year. Since then, MACK shares have increased by 9.2% and is now trading at $12.52.
View the best growth stocks for 2023 here.
When is Merrimack Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our MACK earnings forecast.
How were Merrimack Pharmaceuticals' earnings last quarter?: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) posted its quarterly earnings data on Thursday, March, 9th. The biopharmaceutical company reported ($0.03) EPS for the quarter.
What ETFs hold Merrimack Pharmaceuticals' stock?: ETFs with the largest weight of Merrimack Pharmaceuticals (NASDAQ:MACK) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC),
When did Merrimack Pharmaceuticals' stock split?: Merrimack Pharmaceuticals's stock reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Merrimack Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

What is Merrimack Pharmaceuticals' stock symbol?: Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."
Who are Merrimack Pharmaceuticals' major shareholders?: Merrimack Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Madison Avenue Partners LP (3.88%), Dimensional Fund Advisors LP (3.27%), Sio Capital Management LLC (1.91%), BlackRock Inc. (1.56%), Susquehanna International Group LLP (0.00%) and Wittenberg Investment Management Inc. (1.39%). Insiders that own company stock include Ana Radeljevic, Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen.
View institutional ownership trends.
How do I buy shares of Merrimack Pharmaceuticals?: Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Merrimack Pharmaceuticals' stock price today?: One share of MACK stock can currently be purchased for approximately $12.52.
How much money does Merrimack Pharmaceuticals make?: Merrimack Pharmaceuticals (NASDAQ:MACK) has a market capitalization of $178.54 million. The biopharmaceutical company earns $-1,540,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.
How many employees does Merrimack Pharmaceuticals have?: The company employs 426 workers across the globe.
How can I contact Merrimack Pharmaceuticals?: Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The official website for the company is www.merrimackpharma.com. The biopharmaceutical company can be reached via phone at 617-720-8606, via email at ir@merrimack.com, or via fax at 617-491-1386.

This page (NASDAQ:MACK) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial